Britain’s medical costs regulator, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly And Co’s (NYSE:LLY) weight-loss drug Mounjaro for certain patients with obesity. Unlike its stance on Novo Nordisk A/S’s (NYSE:NVO) rival drug Wegovy, NICE has not imposed a time limit on Mounjaro’s usage. NICE’s draft guidelines suggest that Mounjaro, chemically known as tirzepatide and sold as Zepbound in the U.S., should be available for patients with a body mass index (BMI) of at least 35 and one or more weight-related health conditions, such as type 2 diabetes or heart disease. Also Read: Novo Nordisk Sues ...